       |
IVAX Diagnostics, Inc. is headquartered in Miami, Florida and develops, manufactures and markets proprietary diagnostic reagents, instrumentation and software worldwide through its three subsidiaries; Diamedix Corporation, Delta Biologicals S.r.l. and ImmunoVision, Inc.
IVAX Diagnostics, Inc. was created as a result of the merger on March 14, 2001 between b2bstores.com, Inc. and the diagnostic business subsidiary of IVAX Corporation. On January 26, 2006 , IVAX Corporation was merged into a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. (Teva). As a result of that merger, Teva, indirectly through its IVAX Corporation subsidiary, owned approximately 72% of IVAX Diagnostics. On September 2, 2008 , Teva sold its shareholding in IVAX Diagnostics to a group located in France , which, on September 1, 2010 , sold its shareholding to ERBA Diagnostics Mannheim GmbH, an in vitro diagnostics company headquartered in Germany (ERBA) , a wholly owned subsidiary of a leading Indian company, Transasia Bio-Medicals Ltd. (Transasia) which is headed by leading entrepreneur Suresh Vazirani. As a result, ERBA owns approximately 72.5% of the outstanding shares of IVAX Diagnostics' common stock. Suresh Vazirani was appointed as Executive Chairman of the Board of Directors and Kevin Clark was elevated as Chief Executive Officer, Chief Operating Officer and President.
IVAX Diagnostics' common stock trades under the ticker symbol IVD on the American Stock Exchange.Diamedix Corporation develops and manufactures in vitro diagnostics kits that it markets in conjunction with its MAGO® Plus instruments for use in clinical and hospital laboratories.
ImmunoVision, Inc. develops manufactures and markets autoimmune reagents and research products for use in clinical laboratories, research laboratories and other diagnostic manufacturing companies.
Delta
Biologicals, S.r.l. develops scientific instrumentation, manufactures the
MAGO® Plus instrument and distributes in
vitro diagnostic products to public hospitals and private medical laboratories
in Italy and other international markets.
For
recent press releases and SEC filings
To
provide you with a better background on IVAX Diagnostics, please click the above
link to view some of our recent press releases and SEC filings. Additional information
may be obtained via email to 
or through the web sites for our three subsidiaries.
Thank you again for your interest in IVAX Diagnostics, Inc. — we encourage you to visit this site frequently for updates and additional information.
